Literature DB >> 28906056

Perioperative management of haemophilia A using recombinant factor VIII Fc fusion protein in a patient undergoing endoscopic nasal pituitary adenomectomy for a growth hormone-producing pituitary adenoma.

A Okamoto1, K Yamamoto1, G Eguchi1, T Yamaguchi1, N Nishi2, T Yamada2, E Chen3, Y Maeda1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28906056     DOI： 10.1111/hae.13347

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  2 in total

Review 1.  Recombinant factor VIII Fc for the treatment of haemophilia A.

Authors:  Cedric Hermans; Maria Elisa Mancuso; Beatrice Nolan; K John Pasi
Journal:  Eur J Haematol       Date:  2021-03-31       Impact factor: 2.997

2.  Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.

Authors:  Anna-Elina Lehtinen; Fariba Baghaei; Jan Astermark; Pål André Holme
Journal:  Haemophilia       Date:  2022-05-16       Impact factor: 4.263
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.